Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Inc. and Marvell Technology Group Ltd. Jump As Stocks Sink

By Demitri Kalogeropoulos - Apr 5, 2016 at 7:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Why these two stocks rose even as the broader market declined.

Stocks never broke into positive territory on Tuesday and sold off in the final hour of trading to end up at session lows. By the closing bell, the Dow Jones Industrial Average (^DJI 0.60%) had lost 133 points, or 0.8%, and the S&P 500 (^GSPC 0.95%) shed 21 points, or 1.1%.

^INX Chart

^INX data by YCharts.

Two reports on Tuesday morning showed continued steady growth in the economy. The Markit Purchasing Managers Index found that the service sector rebounded in March following a decline the prior month and the latest Institute for Supply Management report showed that growth in non-manufacturing businesses accelerated last month. Both readings came in slightly stronger than expected.

Meanwhile, Pfizer (PFE 0.56%) and Marvell Technology (MRVL 2.98%) each made notable moves higher on Tuesday even as the broader market declined.

Pfizer's higher tax rate
Drug giant Pfizer notched the Dow's biggest daily gain, rising 2% on almost six times its average trading volume (an amazing 271 million shares traded hands over the course of the day). The surge came after the U.S. Treasury Department issued new rules regarding corporate tax inversions that effectively removed a key financial justification for Pfizer's $160 billion merger with Ireland-based Allergen, whose stock dove 15% on Tuesday.

Image source: Pfizer.

The regulations now in place make it harder for companies to lower their tax liability by changing their residency to outside of the U.S. "Today, we are announcing additional actions to further rein in inversions," Treasury Secretary Jacob Lew said in a press release.  

In their own joint press statement, Pfizer and Allergen said the two companies are "conducting a review" of the new tax regulations. "We won't speculate on any potential impact," they explained to investors, "prior to completing the review."

But Reuters, citing an inside source, reported that Pfizer is "leaning toward abandoning" its merger agreement rather than trying to adjust the terms so that they might fit under the new guidelines.

In any case, Wall Street is betting that Pfizer's business will do better on its own, sending shares higher as the gigantic merger prospects declined.

Marvell Technology's new management team
Marvell Technology's shares soared 13% after the company announced a big shakeup of its management team. The information technology giant's CEO, Sehat Sutardja, and President Weili Dai are stepping down from their positions, effective immediately. "The board [of directors] believes that the time has come to move in a new leadership direction," executives explained in a press release. 

Image source: Marvell Technology.

The move comes as Marvell is still searching for a replacement Chief Financial Officer in the wake of accounting issues that delayed the filing of its latest 10-K annual report. That restatement is expected to include an amended filing of at least two quarterly reports from fiscal 2016, and the company reiterated on Tuesday that it would make the filing "as soon as practicable."

Despite the uncertainty surrounding its accounting procedures -- and its management team -- investors reacted positively to the news that Marvell is making a break from its recent past. The board of directors didn't provide any detail as to what type of leadership shareholders can expect going forward, except to say that its "highest priority is to leverage Marvell's strong core business and technology to drive the next stage of product innovation and profitable growth."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$32,120.28 (0.60%) $191.66
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$3,978.73 (0.95%) $37.25
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.71 (0.56%) $0.30
Marvell Technology Group Ltd. Stock Quote
Marvell Technology Group Ltd.
$53.96 (2.98%) $1.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.